Date:
May 16, 2022
Issue #:
1650
Summary:
The FDA has approved Tarpeyo (Calliditas), a delayed-release
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger’s disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.
capsule formulation of the corticosteroid
budesonide, to reduce proteinuria in adults with
primary immunoglobulin A nephropathy (IgAN; also
called Berger’s disease) who are at risk of rapid
disease progression. It is the fi rst drug to be approved
in the US for this indication. Oral formulations
of budesonide have been available for years for
treatment of inflammatory bowel disease.
